Odyssey Therapeutics Q2 FY26 net loss widens to $52.8 million

• Odyssey Therapeutics posted a GAAP net loss of $52.8 million in Q2 2026, widening from a $41.2 million loss a year earlier.
• R&D expense rose to $36.2 million from $30.2 million, while G&A expense fell to $10.5 million from $13.2 million.
• Non-GAAP adjusted net loss was $38.4 million, excluding $8.7 million of non-cash fair-value charges and $5.7 million of stock-based compensation.
• Cash, cash equivalents and marketable securities totaled $433.1 million at June 30, expected to fund operations into the second half of 2028.
• OD-001 Phase 2a data were accepted for an October oral presentation; Phase 2b monotherapy and Phase 2a vedolizumab-combination trials are expected to start in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-331512), on August 04, 2026, and is solely responsible for the information contained therein.